A brain injury results when the brain suffers a physical trauma, exposing it to a force greater than it can handle. These force-induced disruptions of the brain can result in a variety of structural, physiological, and functional deficits. A traumatic brain injury (TBI) is a type of physical brain injury that results from a violent blow or jolt to the head. The effects of a TBI range from mild to severe and can include physical, cognitive, and emotional deficits. Mild TBIs can cause concussions, while more severe injuries can result in coma or brain death. Physically, brain injuries can cause a vast array of damage to the brain. Trauma can lead to physical damage to brain cells, disruption of neuronal pathways, and inflammation of the brain. Cognitively, TBI can affect memory, language, planning and reasoning skills, and executive functioning. Emotional effects may include depression, anxiety, and aggression. The treatment of TBI is a multi-faceted approach depending on the severity of the injury. Mild injuries may only require the administration of medications to reduce swelling. More severe TBIs may require more intensive interventions such as surgery and rehabilitation. Rehabilitation is a crucial component of treatment, as it allows the patient to regain strength and relearn skills that have been affected by the injury. Brain injury can significantly change a person’s life. It can lead to long-term physical, cognitive, and psychological disabilities. As such, it is important that those who have sustained a TBI be provided with the support and resources necessary to move forward with their lives. With the right help and resources, those who have a brain injury can learn to live a fulfilling and meaningful life.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States